Peter J.  Mariani net worth and biography

Peter Mariani Biography and Net Worth

CFO of AxoGen

Peter J. Mariani currently works at CytoSorbents Corp., as Chief Financial Officer from 2024. Mr. Mariani also formerly worked at Guidant Vascular Intervention, as Director-Financial Reporting from 1996 to 1998, Guidant Corp., as Chief Accounting Officer, VP & Controller from 2006 to 2011, Hansen Medical, Inc., as Chief Financial Officer from 2011 to 2014, LENSAR, Inc., as Chief Financial Officer from 2014 to 2016, Axogen Corp., as Chief Financial Officer & Executive Vice President, Harlan Laboratories, Inc., as Chief Financial Officer from 2007 to 2009, BMWC Constructors, Inc., as Chief Financial Officer from 2009 to 2010, Guidant Japan KK, as Vice President-Finance & Administration from 1998 to 2002, and Axogen, Inc., as Chief Financial Officer & Executive Vice President from 2021 to 2023.

Mr. Mariani received his undergraduate degree in 1987 from Indiana University.

What is Peter J. Mariani's net worth?

The estimated net worth of Peter J. Mariani is at least $13.18 million as of December 13th, 2024. Mariani owns 401,363 shares of AxoGen stock worth more than $13,184,775 as of December 4th. This net worth evaluation does not reflect any other investments that Mariani may own. Learn More about Peter J. Mariani's net worth.

How do I contact Peter J. Mariani?

The corporate mailing address for Mariani and other AxoGen executives is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. AxoGen can also be reached via phone at (386) 462-6800 and via email at [email protected]. Learn More on Peter J. Mariani's contact information.

Has Peter J. Mariani been buying or selling shares of AxoGen?

Peter J. Mariani has not been actively trading shares of AxoGen within the last three months. Most recently, Peter J. Mariani sold 12,500 shares of the business's stock in a transaction on Monday, December 11th. The shares were sold at an average price of $7.50, for a transaction totalling $93,750.00. Following the completion of the sale, the chief financial officer now directly owns 63,603 shares of the company's stock, valued at $477,022.50. Learn More on Peter J. Mariani's trading history.

Who are AxoGen's active insiders?

AxoGen's insider roster includes P Burke (Director), Erick Devinney (Insider), Michael Donovan (VP), Gregory Freitag (Director), Peter Mariani (CFO), Maria Martinez (Insider), Guido Neels (Director), Joseph Tyndall (Director), Amy Wendell (Director), and Karen Zaderej (CEO). Learn More on AxoGen's active insiders.

Are insiders buying or selling shares of AxoGen?

In the last twelve months, insiders at the medical equipment provider sold shares 16 times. They sold a total of 173,773 shares worth more than $3,429,182.24. The most recent insider tranaction occured on November, 11th when Director William P Mr. Burke sold 3,591 shares worth more than $86,255.82. Insiders at AxoGen own 2.8% of the company. Learn More about insider trades at AxoGen.

Information on this page was last updated on 11/11/2025.

Peter J. Mariani Insider Trading History at AxoGen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/11/2023Sell12,500$7.50$93,750.0063,603View SEC Filing Icon  
1/31/2023Sell14,320$9.55$136,756.0055,555View SEC Filing Icon  
1/26/2023Sell20,939$9.90$207,296.1042,108View SEC Filing Icon  
11/16/2022Sell10,649$11.88$126,510.1229,698View SEC Filing Icon  
12/29/2020Sell1,293$17.81$23,028.3311,669View SEC Filing Icon  
12/21/2020Sell481$16.42$7,898.026,900View SEC Filing Icon  
10/30/2020Sell75,683$12.41$939,226.0380,683View SEC Filing Icon  
10/7/2016Buy3,333$7.50$24,997.503,333View SEC Filing Icon  
See Full Table

Peter J. Mariani Buying and Selling Activity at AxoGen

This chart shows Peter J Mariani's buying and selling at AxoGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AxoGen Company Overview

AxoGen logo
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
Read More

Today's Range

Now: $32.85
Low: $30.24
High: $34.24

50 Day Range

MA: $21.72
Low: $15.59
High: $32.85

2 Week Range

Now: $32.85
Low: $9.22
High: $34.24

Volume

3,164,205 shs

Average Volume

740,537 shs

Market Capitalization

$1.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06